Biopas
Biopas is a Bogota-headquartered pharmaceutical commercialization platform (subsidiary of Swixx Biopharma, Switzerland) that helps global manufacturers launch and grow innovative specialty drugs across Latin America through owned subsidiaries in eight countries, providing regulatory, medical, market access, and distribution services.
- Company typePrivate
- Founded2002
- HeadquartersBogotá, Colombia
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Biopas does
Biopas is a Bogota-headquartered biopharmaceutical commercialization platform that operates as a subsidiary of Swiss-based Swixx Biopharma AG. Founded in 2002, the company provides end-to-end launch and growth infrastructure for global pharmaceutical manufacturers seeking to bring innovative specialty products into Latin American markets. Its core platform integrates sales, marketing, medical affairs, market access, regulatory affairs, pharmacovigilance, supply chain, and compliance services, delivered through fully owned subsidiaries in at least eight countries (Brazil, Argentina, Colombia, Mexico, Chile, Peru, Guatemala, Costa Rica) supported by QC laboratories in Brazil and Argentina and a network of certified cold-chain 3PL partners.
The company maintains 600+ active Marketing Authorizations across the region and specializes in therapy areas where global pharma typically faces launch complexity in LATAM: CNS, immunology, dermatology, oncology, gastroenterology, and rare/orphan diseases. Its named partner roster spans major and specialty manufacturers including AstraZeneca, UCB, Lundbeck, Ipsen, Jazz Pharmaceuticals, Daiichi Sankyo, Chiesi, LEO Pharma, Merz Therapeutics, Ferring, Bial, Acorda, Mirum, Proveca, and others. Direct-to-HCP commercial engagement is supported by field sales and medical detailing teams, while a dedicated healthcare-professional portal (BiopasMed) channels scientific and product information to prescribers.
Biopas operates a 350+ employee organization led by founders Pascal Forget (Executive Regional General Manager LATAM) and Maria Fernanda Forget (COO LATAM), with a full CXO bench drawn from Pfizer, Abbott, AbbVie, Sanofi, and Biogen. The company's revenue model is contract-based: global pharma partners grant product commercialization rights for defined LATAM territories in multi-year contracts, and Biopas earns margins on sales and services. ISO 37001:2016 anti-bribery certification, alignment with EMA/FDA QC standards, and adherence to WHO/PAHO pharmacovigilance guidelines underpin the governance posture required by multinational partners.
Biopas firmographics
Firmographics- Name
- Biopas
- Legal name
- Biopas
- Website
- https://biopasgroup.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Biopas is a Bogota-headquartered pharmaceutical commercialization platform (subsidiary of Swixx Biopharma, Switzerland) that helps global manufacturers launch and grow innovative specialty drugs across Latin America through owned subsidiaries in eight countries, providing regulatory, medical, market access, and distribution services.
- Ownership category
- akta.pro rank
Biopas industry classification
Industry- Product category
- Pharmaceutical Commercialization Services
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Pharmacy & Biologics Distribution (CRAOAHAD)
- akta.pro secondary industries
- Biologics & Biosimilars Distributors (HLAIAJAH), Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution) (HLAAAHAL), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)
Keywords
Where Biopas is headquartered
LocationHeadquarters
- HQ city
- Bogotá
- HQ country
- Colombia
- HQ region
- Latin America
Offices10 records
Markets served
Biopas business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Infrastructure, Others
Revenue model
- Pharmaceutical Product Commercialization: Biopas generates revenue by commercializing innovative pharmaceutical products from global pharmaceutical partners in the Latin American region. The company provides end-to-end services including sales, marketing, medical affairs, market access, regulatory, and distribution, earning margins on product commercialization through established partnerships with major pharmaceutical companies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B pharmaceutical partnership model |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Biopas product offering
Product offeringCore offering
Biopas commercializes innovative pharmaceutical products from global pharmaceutical partners across Latin America through fully owned subsidiaries. It provides end-to-end pharmaceutical commercialization services including sales, marketing, medical affairs, market access, regulatory and quality management, pharmacovigilance, supply chain distribution, and patient support programs across CNS, immunology, dermatology, oncology, gastroenterology, and orphan drug therapy areas.
Product overview
Biopas, a Swixx Biopharma company, operates as a comprehensive pharmaceutical commercialization platform in Latin America. The company provides a unified portfolio of integrated services including Marketing, Medical Affairs, Market Access, Patient Support Programs, Compliance, Regulatory & Quality, Supply Chain, and Pharmacovigilance services. Operating across CNS, immunology, dermatology, oncology, gastroenterology, and orphan drugs with over 600 active Marketing Authorizations and 350+ employees, Biopas serves as a turnkey solution for launching and growing pharmaceutical products in the region through fully owned subsidiaries.
Differentiator
Problem solved
Functional benefit
Brands
- BiopasMed: Exclusive portal for healthcare professionals in Latin America
Products and services
- Pharmaceutical Commercialization Platform
Quantifiable outcome
- Maintains 600+ active Marketing Authorizations across Latin America
- +1 more outcomes
Companies that use Biopas
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Biopas technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Biopas partnerships and signals
Strategic signalPartnerships
23 partnerships are on record, tiered core and minor.
- Acorda TherapeuticscorePharmaceutical partnership for commercializing innovative products in Latin America. Biopas provides commercialization platform while Acorda supplies specialty pharmaceutical products.
- AstraZenecacoreMajor global pharmaceutical company partnership for commercializing products across LATAM markets including CNS, immunology, and other therapy areas.
- BialcorePortuguese pharmaceutical company partnership for commercializing innovative medicines in Latin America.
- ChiesicoreItalian pharmaceutical company partnership for product commercialization in LATAM markets.
- Daewoong PharmaceuticalcoreSouth Korean pharmaceutical company partnership for commercializing products in Latin America.
- Daiichi SankyocoreJapanese pharmaceutical company partnership for commercializing innovative pharmaceutical products across LATAM.
- Ferring PharmaceuticalscoreSpecialty pharma partnership for reproductive medicine and other specialized therapeutic areas in Latin America.
- IpsencoreFrench pharmaceutical company partnership for commercializing specialty medicines in LATAM markets.
- Jazz PharmaceuticalscoreIrish pharmaceutical company partnership for commercializing innovative therapies including psychiatry and neurology products in Latin America.
- LEO PharmacoreDanish pharmaceutical company specializing in dermatology, partnership for skin disease treatments in LATAM.
- LFBcoreFrench biopharmaceutical company partnership for plasma-derived medicines commercialization in Latin America.
- LundbeckcoreDanish pharmaceutical company specializing in CNS disorders, partnership for neuroscience products in LATAM.
- Merz TherapeuticscoreGerman pharmaceutical company partnership for commercializing neurology and aesthetic medicine products in Latin America.
- UCBcoreBelgian pharmaceutical company partnership for immunology and neurology products commercialization in LATAM.
- CheplapharmminorGerman pharmaceutical company partnership for commercializing established branded medicines in Latin America.
- CaromedminorMedical devices and pharmaceutical products partnership for Latin American markets.
- Dr. PflegerminorGerman pharmaceutical company partnership for product commercialization in LATAM.
- Mayoly SpindlerminorFrench pharmaceutical company partnership for gastroenterology and other specialty products in Latin America.
- MediceminorGerman pharmaceutical company partnership for commercializing medicines in Latin America.
- Mirum PharmaceuticalscoreSpecialty pharmaceutical company partnership for rare disease medicines in Latin America.
- Neurim PharmaceuticalscoreIsraeli pharmaceutical company specializing in CNS disorders, partnership for neuroscience products in LATAM.
- PharmanoviaminorSwiss pharmaceutical company partnership for commercializing established medicines across LATAM.
- Proveca PharmaminorUK specialty pharmaceutical company partnership for pediatric medicines in Latin America.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Biopas competitors and assessment
Company assessmentDirect peers
- Adium Pharma: Latin American specialty pharmaceutical commercialization company that partners with global pharma to bring innovative medicines to LATAM markets. Most directly comparable peer to Biopas by business model and regional focus.
- Megalabs: Latin American pharmaceutical group with a broad specialty and branded generics portfolio distributed across multiple LATAM countries. Comparable to Biopas as a multi-country LATAM pharma operator with partner-driven commercialization.
- Grupo Insud (Insud Pharma): Spanish-Argentine pharmaceutical group operating across branded, OTC, and specialty medicine commercialization in LATAM and Europe. Comparable partner-driven, multi-country pharmaceutical commercialization model.
- Exeltis: Global specialty pharmaceutical company with strong women's health and specialty care presence across LATAM. Operates a similar partner-led commercialization model in Latin American markets.
Broad incumbents
- Genomma Lab: Large Mexican/LATAM pharmaceutical company commercializing branded pharmaceutical and personal-care products across Latin America. Broader incumbent with overlapping LATAM commercialization capabilities.
- Eurofarma: Brazilian-headquartered multinational pharmaceutical company with manufacturing and commercialization across Latin America. Comparable as a major LATAM-headquartered pharma operator serving similar geographic footprint.
- AstraZeneca LATAM: Global biopharmaceutical company operating its own LATAM commercial organization across the same countries Biopas serves — both as a current Biopas partner and as a benchmark for what an in-house alternative could look like.
Regional players
- Cristália: Brazilian pharmaceutical manufacturer and commercializer across multiple therapeutic categories. Comparable primarily within the Brazilian pharma market that Biopas treats as a core country.
- Biolab Sanus: Brazilian pharmaceutical company commercializing branded specialty medicines in Brazil and select LATAM markets. Comparable to Biopas within the Brazilian specialty pharma commercialization segment.
- Asofarma: Mexican pharmaceutical group with branded generics and specialty pharma portfolios across Mexico and Central America. Comparable LATAM specialty pharmaceutical operator.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Biopas social profiles
Digital presenceBiopas compliance and trust
Trust signalCompliance1 record
Biopas financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biopas leadership team
Management profileNumber of profiles
Profiles6 records
Biopas funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biopas M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biopas
What does Biopas do?
Biopas commercializes innovative pharmaceutical products from global pharmaceutical partners across Latin America through fully owned subsidiaries. It provides end-to-end pharmaceutical commercialization services including sales, marketing, medical affairs, market access, regulatory and quality management, pharmacovigilance, supply chain distribution, and patient support programs across CNS, immunology, dermatology, oncology, gastroenterology, and orphan drug therapy areas.
Is Biopas a public or private company?
Biopas is a private company. It is classified as corporate owned and is currently operating.
When was Biopas founded?
Biopas was founded in 2002. It employs 251 to 500 people.
Where is Biopas based?
Biopas is headquartered in Bogotá, Colombia, in the Latin America region.
How does Biopas make money?
One revenue line is on record: pharmaceutical Product Commercialization.
Who are Biopas's main competitors?
Direct peers on record are Adium Pharma, Megalabs, Grupo Insud (Insud Pharma) and Exeltis. Broad incumbents are Genomma Lab, Eurofarma and AstraZeneca LATAM. Regional players are Cristália, Biolab Sanus and Asofarma.
Does Biopas have an API?
No public API is recorded for Biopas.
What industry is Biopas in?
Biopas's product category is Pharmaceutical Commercialization Services. Its primary akta.pro industry code is CRAOAHAD, Specialty Pharmacy & Biologics Distribution, with a secondary code of HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 424210 and its SIC code is 5122.